Will pathogen reduction of blood components harm more people than it helps in developed countries?

Transfusion

Volumn 56, Issue 5, 2016, Pages 1236-1241

  Hess, John R ^a   Pagano, Monica B ^a   Barbeau, James D ^b   Johannson, Pär I ^c,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN;

BLOOD COMPONENT; DEVELOPED COUNTRY; DISEASE ASSOCIATION; GRAFT VERSUS HOST REACTION; HUMAN; INFECTIOUS COMPLICATION; MORTALITY; PATHOGEN REDUCTION SYSTEM; PLASMA; RESUSCITATION; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTE; ULTRAVIOLET RADIATION; ADVERSE EFFECTS; BLOOD COMPONENT THERAPY; BLOOD SAFETY; BLOODBORNE BACTERIUM; DISEASE TRANSMISSION; META ANALYSIS; PREVENTION AND CONTROL;

BLOOD COMPONENT TRANSFUSION; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; DEVELOPED COUNTRIES; DISEASE TRANSMISSION, INFECTIOUS; HUMANS;

EID: 84966668103     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13512     Document Type: Review

References (35)

1. Alter HJ, Klein HG., The hazards of blood transfusion in historical perspective. Blood 2008; 112: 2617-26.
2. Stramer SL, Dodd RY,; AABB Transfusion-Transmitted Diseases Emerging Infectious Diseases Subgroup. Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion 2013; 53: 2375-83.
3. Dodd RY., Current risk for transfusion transmitted infections. Curr Opin Hematol 2007; 14: 671-6.
4. Janka J, Maldarelli F., Prion diseases: update on mad cow disease, variant Creutzfeldt-Jakob disease, and the transmissible spongiform encephalopathies. Curr Infect Dis Rep 2004; 6: 305-15.
5. Dodd RY., Bacterial contamination and transfusion safety: experience in the United States. Transfus Clin Biol 2003; 10: 6-9.
6. de Korte D, Curvers J, de Kort WL, et al., Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion 2006; 46: 476-85.
7. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2013 [Internet]. Rockville (MD): FDA/Center for Biologics Evaluation and Research; 2013 [cited 2015 Sep 7]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Safety Availability/ReportaProblem/TransfusionDonationFatalities/UCM393080.pdf.
8. Salunkhe V, van der Meer PF, de Korte D, et al., Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci 2015; 52: 19-34.
9. Roback JD, Caldwell S, Carson J, et al., Evidence-based practice guidelines for plasma transfusion. Transfusion 2010; 50: 1227-39.
10. Slichter SJ, Kaufman RM, Assmann SF, et al., Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-13.
11. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-71.
12. Armand R, Hess JR., Treating coagulopathy in trauma patients. Transfus Med Rev 2003; 17: 223-31.
13. Rhee P, Joseph B, Pandit V, et al., Increasing trauma deaths in the United States. Ann Surg 2014; 260: 13-21.
14. Baker CC, Oppenheimer L, Stephens B, et al., Epidemiology of trauma deaths. Am J Surg 1980; 140: 144-50.
15. Dutton RP, Stansbury LG, Leone S, et al., Trauma mortality in mature trauma systems: are we doing better? An analysis of trauma mortality patterns, 1997-2008. J Trauma 2010; 69: 620-6.
16. Shrestha B, Holcomb JB, Camp EA, et al., Damage-control resuscitation increases successful nonoperative management rates and survival after severe blunt liver injury. J Trauma Acute Care Surg 2015; 78: 336-41.
17. Holcomb JB, Tilley BC, Baraniuk S, et al., Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015; 313: 471-82.
18. Butler C, Doree C, Estcourt LJ, et al., Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2013; 3: CD009072.
19. Roth V, Kuehnert MJ, Haley NR, et al., Evaluation of a reporting system for bacterial contamination of blood components in the United States. Transfusion 2001; 41: 1486-92.
20. Lafeuillade B, Eb F, Ounnoughene N, et al., Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French national hemovigilance network from 2000 to 2008. Transfusion 2015; 55: 636-46.
21. de Biasi AR, Stansbury LG, Dutton RP, et al., Blood product use in trauma resuscitation: plasma deficit versus plasma ratio as predictors of mortality in trauma (CME). Transfusion 2011; 51: 1925-32.
22. INTERCEPT plasma [Internet]. Concord (CA): Cerus Corp.; 2016 [cited 2015 Sep 19]. Available from: http://www.interceptbloodsystem.com/product-overview/intercept-plasma.
23. Larrea L, Ortiz-de-Salazar MI, Martínez P, et al., Quantitative analysis of plasma proteins in whole blood-derived fresh frozen plasma prepared with three pathogen reduction technologies. Transfus Apher Sci 2015; 52: 305-10.
24. Snyder E, Raife T, Lin L, et al., Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet a light. Transfusion 2004; 44: 1732-40.
25. Murphy S, Snyder E, Cable R, et al., Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet a light. Transfusion 2006; 46: 24-33.
26. Vamvakas EC., Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012; 102: 302-16.
27. van Rhenen D, Gulliksson H, Cazenave JP, et al., Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-33.
28. McCullough J, Vesole DH, Benjamin RJ, et al., Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004; 104: 1534-41.
29. Janetzko K, Cazenave JP, Klüter H, et al., Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 45: 1443-52.
30. Kerkhoffs JL, van Putten WL, Novotny VM, et al., Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-17.
31. Lozano M, Knutson F, Tardivel R, et al., A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153: 393-401.
32. Johansson PI, Stensballe J., Effect of haemostatic control resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sang 2009; 96: 111-8.
33. Langan NR, Eckert M, Martin MJ., Changing patterns of in-hospital deaths following implementation of damage control resuscitation practices in US forward military treatment facilities. JAMA Surg 2014; 149: 904-12.
34. Dzik WS, Ziman A, Cohen C, et al., Survival after ultramassive transfusion: a review of 1360 cases. Transfusion 2016; 56: 558-63.
35. Cook RJ, Heddle NM., Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations. Transfusion 2013; 53: 1843-55.